Characteristics | Alive | Dead | p | OR (95% CI) |
---|---|---|---|---|
Age, yrs, ± SD (n) | 58.4 ± 13.0 (420) | 70.4 ± 13.7 (44) | < 0.001 | 1.08 (1.05–1.11) |
Duration PsA, yrs, ± SD (n) | 20.3 ± 10.9 (419) | 21.4 ± 13.7 (44) | 0.566 | 1.01 (0.98–1.04) |
Duration PsO, yrs, ± SD (n) | 29.9 ± 14.9 (399) | 37.9 ± 19.3 (39) | 0.003 | 1.03 (1.01–1.05) |
BMI, ± SD (n) | 27.7 ± 5.2 (370) | 27.2 ± 4.7 (30) | 0.636 | 0.98 (0.91–1.06) |
DAI, mean ± SD (n) | 3.87 ± 0.82 (411) | 4.49 ± 1.13 (43) | < 0.001 | 1.94 (1.43–2.64) |
Male | 209 (50) | 25 (57) | 0.373 | 0.75 (0.40–1.41) |
Smoking (ever) | 224 (54) | 24 (60) | 0.505 | 1.25 (0.65–2.43) |
Hypertension | 181 (43) | 24 (55) | 0.157 | 1.56 (0.84–2.92) |
Hyperlipidemia | 66 (16) | 5 (11) | 0.435 | 0.68 (0.26–1.79) |
Diabetes | 49 (12) | 9 (20) | 0.099 | 1.93 (0.87–4.25) |
Destructive/deforming disease | 204 (49) | 29 (67) | 0.021 | 2.16 (1.11–4.21) |
bDMARD (ever) | 55 (13) | 2 (4.5) | 0.098 | 0.31 (0.74–1.34) |
sDMARD (ever) | 285 (68) | 27 (61) | 0.383 | 0.75 (0.40–1.43) |
NSAID (ever) | 303 (72) | 24 (54) | 0.014 | 0.46 (0.24–0.86) |
Oral corticosteroid treatment (ever) | 123 (29) | 20 (46) | 0.028 | 2.00 (1.07–3.76) |
Fulfilling CASPAR criteria | 378 (90) | 40 (91) | 0.882 | 1.08 (0.37–3.18) |
Polyarthritis (according to Moll and Wright)* | 173 (41) | 24 (54) | 0.088 | 1.71 (0.92–3.20) |
Dactylitis (ever) | 119 (41) | 10 (33) | 0.421 | 0.72 (0.33–1.60) |
Nail involvement (ever) | 162 (53) | 16 (48) | 0.640 | 0.84 (0.41–1.73) |
Axial involvement | 65 (15) | 14 (32) | 0.006 | 2.54 (1.28–5.05) |
Axial and peripheral joint involvement | 35 (8.3) | 11 (24) | < 0.001 | 3.65 (1.70–7.86) |
↵* 1973 Moll and Wright criteria for PsA. PsA: psoriatic arthritis; PsO: psoriasis; BMI: body mass index; DAI: disease activity index; DMARD: disease-modifying antirheumatic drug; bDMARD: biological DMARD; sDMARD: synthetic DMARD; NSAID: nonsteroidal antiinflammatory drug; CASPAR: ClASsification for Psoriatic ARthritis (criteria).